Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading OGEN daily closes…
Loading price history…
Pipeline assets
ONP-002
Phase 2 · ActiveModality: small molecule
Indications
Mild traumatic brain injury (mTBI)(Phase 2)
Status note Lead product candidate; synthetic neurosteroid formulation for mTBI, delivered via intranasal device. Completed a Phase 1 clinical trial in healthy human subjects; company conducting Phase 2 work and nonclinical studies.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.